Literature DB >> 10473222

The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents.

V T Andriole1.   

Abstract

Invasive fungal infections are a major problem in immunocompromised patients. The recent expansion of antifungal drug research has occurred because there is a critical need for new antifungal agents to treat these life-threatening invasive infections. The overview of the development of antifungal therapy which is provided herein reflects the increased interest in this very special area of infectious diseases. Although we have newer, less toxic, antifungal agents that are available for clinical use, their clinical efficacy in some invasive fungal infections, such as aspergillosis and fusariosis, is not optimal. Thus, intense efforts in antifungal drug discovery are still needed to develop more promising and effective antifungal agents for use in the clinical arena.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473222     DOI: 10.1093/jac/44.2.151

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

Review 1.  SPK-843 (Aparts/Kaken).

Authors:  Noer Kasanah; Mark T Hamann
Journal:  Curr Opin Investig Drugs       Date:  2005-08

2.  Broad-Spectrum Antiviral Activity of 3'-Deoxy-3'-Fluoroadenosine against Emerging Flaviviruses.

Authors:  Luděk Eyer; Pavel Svoboda; Jan Balvan; Tomáš Vičar; Matina Raudenská; Michal Štefánik; Jan Haviernik; Ivana Huvarová; Petra Straková; Ivo Rudolf; Zdeněk Hubálek; Katherine Seley-Radtke; Erik de Clercq; Daniel Růžek
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

3.  In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent.

Authors:  Yasuki Kamai; Tamako Harasaki; Takashi Fukuoka; Satoshi Ohya; Katsuhisa Uchida; Hideyo Yamaguchi; Shogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Authors:  Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Authors:  Julien P Maincent; Laura K Najvar; William R Kirkpatrick; Siyuan Huang; Thomas F Patterson; Nathan P Wiederhold; Jay I Peters; Robert O Williams
Journal:  Drug Dev Ind Pharm       Date:  2016-10-05       Impact factor: 3.225

6.  Expression of genes encoding innate host defense molecules in normal human monocytes in response to Candida albicans.

Authors:  Hee Sup Kim; Eun Hwa Choi; Javed Khan; Emmanuel Roilides; Andrea Francesconi; Miki Kasai; Tin Sein; Robert L Schaufele; Kenichi Sakurai; Chang Gue Son; Braden T Greer; Stephen Chanock; Caron A Lyman; Thomas J Walsh
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

7.  In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum.

Authors:  Noboru Tsuchimori; Ryogo Hayashi; Naomi Kitamoto; Kentaro Asai; Tomoyuki Kitazaki; Yuji Iizawa; Katsumi Itoh; Kenji Okonogi
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

8.  Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.

Authors:  D M Kuhn; T George; J Chandra; P K Mukherjee; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls.

Authors:  Richard J Jurevic; Mai Bai; Robert B Chadwick; Theodore C White; Beverly A Dale
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

Review 10.  Fungal biofilms and drug resistance.

Authors:  Mary Ann Jabra-Rizk; William A Falkler; Timothy F Meiller
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.